RHEACELL announces FDA approval for Phase 3 study in refractory, non-curable CVU
mehr
Ergebnis der Suchanfrage nach Feld-
Inhalte
- Kategorie:
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
6 Treffer
Research Success in Rare Disease / RHEACELL receives positive signal for accelerated stem cell development program in rare ‚Butterfly Disease‘
mehr- 2
PM: KI-gestützte Computer Vision ist laut neuestem DHL Trend Report branchenprägende Technologie / PR: AI-driven computer vision has become an industry-shaping technology, finds latest DHL’s Trend Report
mehr RHEACELL announces “First Patient In”: EB-Haus in Salzburg, Austria starts pivotal study for stem cell therapy for severe forms of Epidermolysis bullosa that is longed for by those affected
mehrStem cell therapy for “Butterfly disease” / RHEACELL receives ‘Partners in Progress Award’ from debra of America for Epidermolysis Bullosa research
mehrDaily Recap Day 1 - IFA 2020 Special Edition
mehr
1